Optimi Health raises $15M in oversubscribed offering, uplists to Nasdaq
What's the deal? Optimi Health, a Vancouver-based pharmaceutical company focused on psychedelic drug products, has priced an oversubscribed public offering of 2.4 million common shares at $6.25 each. The deal is expected to bring in roughly $15M in gross proceeds.
The offering coincides with Optimi's uplisting from the Canadian Securities Exchange to the Nasdaq Capital Market, where it began trading on May 20 under the ticker OPTH. The company also completed a 1-for-30 share consolidation on May 19, leaving about 3.2 million shares outstanding before the offering.
The underwriter has an option to purchase up to 360,000 additional shares. Closing is expected on or about May 21.
Why now? Optimi is a commercial-stage company that manufactures and distributes finished psychedelic drug products — a sector gaining regulatory traction in North America. An oversubscribed offering suggests strong investor appetite, and the Nasdaq uplisting gives it access to a deeper pool of US institutional capital.
The company plans to use the proceeds to scale production, expand into new markets, and support working capital.
What could go wrong? The offering dilutes existing shareholders, with new shares representing a significant chunk of the post-consolidation float. Management also retains broad discretion over how the proceeds are allocated, which means investors are largely trusting the team's judgment on deployment.
Psychedelic therapeutics remain a nascent and heavily regulated space. Regulatory setbacks or slower-than-expected market development could undermine the growth thesis underpinning the raise.
The signal: Optimi's oversubscribed round and Nasdaq debut reflect continued investor interest in psychedelic medicine, even as the broader biotech market remains selective. The uplisting trend — small-cap companies moving from junior exchanges to major US boards — signals confidence that mainstream capital markets are warming to the sector. Whether that confidence translates into commercial results is the next test.
Read more: stocktitan.net
